{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T04:55:17Z","timestamp":1781758517375,"version":"3.54.5"},"reference-count":84,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>5\u03b1-reductase inhibitors (5-ARIs) are most commonly used to treat benign prostatic hyperplasia (BPH) and androgenetic alopecia (AGA). Preclinical and clinical studies suggest that in patients with AGA treated with 5-ARIs, a subset reports sexual adverse events, including decreased libido, erectile dysfunction, and ejaculatory disorders. This review explores the development of sexual dysfunction in patients with androgenetic alopecia due to the use of 5-ARIs, emphasizing their importance in the clinical diagnosis of health disorders coexisting with hair loss.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic review was conducted by searching electronic databases, including MEDLINE, Scopus, Web of Science and Google Scholar, according to the PRISMA guidelines. The search was limited to articles published in English and up to December 2025. Key search terms included \u201c5\u03b1-reductase inhibitors\u201d or \u201c5-ARIs\u201d or \u201cfinasteride\u201d or \u201cdutasteride\u201d AND \u201cside effects\u201d or \u201csexual side effects\u201d or \u201csexual\u201d or \u201csexual dysfunction\u201d AND \u201candrogenetic alopecia\u201d or \u201cmale pattern hair loss\u201d or \u201cfemale pattern hair loss.\u201d Data synthesis included findings from 41 studies, comprising 33 primary-evidence studies in AGA\/MPHL\/FPHL populations and 8 supporting-evidence studies providing pharmacokinetic, mixed-indication, or comparative context.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>5-ARIs are effective therapies for androgenetic alopecia and are generally well tolerated. Across placebo-controlled RCTs evaluating oral finasteride 1 mg in men with AGA, sexual adverse events were reported in 1.9\u20136.7% of treated patients compared with 0.9\u20133.9% in placebo groups, with most events mild and reversible upon discontinuation. Topical finasteride 0.25% was associated with lower rates of sexual adverse events (2.8%) compared with oral finasteride (4.8%). For dutasteride 0.5 mg, sexual adverse events ranged from 4.1 to 12.0% across RCTs, compared with 4.0\u20135.0% in placebo groups. No sexual adverse effects were consistently reported in women treated with 5-ARIs for AGA. In most reports, the effects were transient and reversible after discontinuation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Overall, clinicians should counsel patients that most sexual side effects reported in controlled AGA studies are infrequent, mild, and reversible, but individual susceptibility varies. Shared decision-making, careful monitoring of sexual function, and further high-quality long-term studies\u2014using standardized definitions of sexual dysfunction and persistence\u2014are needed to quantify risks better and identify vulnerable subgroups.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1787706","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T04:33:56Z","timestamp":1781757236000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Sexual dysfunction associated with 5\u03b1-reductase inhibitors in the treatment of androgenetic alopecia: a systematic review"],"prefix":"10.3389","volume":"13","author":[{"given":"Aleksandra","family":"Z\u0142otowska","sequence":"first","affiliation":[{"name":"University Centre of General Dermatology and Oncodermatology, Wroc\u0142aw Medical University","place":["Wroc\u0142aw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beata","family":"Jastrz\u0105b-Mi\u015bkiewicz","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Venereology and Clinical Immunology, Faculty of Medicine, Wroc\u0142aw University of Science and Technology","place":["Wroc\u0142aw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr K.","family":"Krajewski","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Venereology and Clinical Immunology, Faculty of Medicine, Wroc\u0142aw University of Science and Technology","place":["Wroc\u0142aw, Poland"]},{"name":"Department of Dermatovenereology, 4th Military Hospital","place":["Wroc\u0142aw, Poland"]},{"name":"L\u00fcbeck Institute of Experimental Dermatology, University of L\u00fcbeck","place":["L\u00fcbeck, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.2147\/CCID.S385861","article-title":"Treatment of androgenetic alopecia: current guidance and unmet needs.","volume":"16","author":"Kaiser","year":"2023","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1159\/000541395","article-title":"Dutasteride for the treatment of androgenetic alopecia: an updated review.","volume":"240","author":"Ding","year":"2024","journal-title":"Dermatology"},{"key":"B3","article-title":"Androgenetic alopecia.","volume-title":"StatPearls.","author":"Ho","year":"2025"},{"key":"B4","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/s40265-023-01880-x","article-title":"Androgenetic alopecia: therapy update.","volume":"83","author":"Devjani","year":"2023","journal-title":"Drugs"},{"key":"B5","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s40257-019-00479-x","article-title":"Female androgenetic alopecia: an update on diagnosis and management.","volume":"21","author":"Starace","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"85","DOI":"10.4103\/npmj.npmj_47_24","article-title":"Androgenetic alopecia: a review.","volume":"31","author":"Oiwoh","year":"2024","journal-title":"Niger Postgrad Med J"},{"key":"B7","article-title":"5\u03b1-reductase inhibitors.","volume-title":"StatPearls.","author":"Salisbury","year":"2025"},{"key":"B8","first-page":"56","article-title":"Adverse effects and safety of 5-alpha reductase inhibitors (finasteride, dutasteride): a systematic review.","volume":"9","author":"Hirshburg","year":"2016","journal-title":"J Clin Aesthet Dermatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1517\/14740338.2013.742885","article-title":"Effects of 5-alpha reductase inhibitors on erectile function, sexual desire and ejaculation.","volume":"12","author":"Gur","year":"2013","journal-title":"Expert Opin Drug Saf"},{"key":"B10","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s11154-015-9319-y","article-title":"Adverse effects of 5\u03b1-reductase inhibitors: what do we know, don\u2019t know, and need to know?","volume":"16","author":"Traish","year":"2015","journal-title":"Rev Endocr Metab Disord"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/00333549131282S101","article-title":"Understanding sexual health and its role in more effective prevention programs.","volume":"128","author":"Douglas","year":"2013","journal-title":"Public Health Rep"},{"key":"B12","doi-asserted-by":"publisher","first-page":"873D","DOI":"10.2471\/BLT.24.291565","article-title":"Associations between sexual health and well-being: a systematic review.","volume":"102","author":"Vasconcelos","year":"2024","journal-title":"Bull World Health Organ"},{"key":"B13","first-page":"141","article-title":"Drug-induced sexual dysfunction.","volume":"1","author":"Aldridge","year":"1982","journal-title":"Clin Pharm."},{"key":"B14","doi-asserted-by":"publisher","first-page":"13030\/qt24k8q743","DOI":"10.5070\/D32311037240","article-title":"Sexual side effects of 5-alpha-reductase inhibitors finasteride and dutasteride: a comprehensive review.","volume":"23","author":"Fertig","year":"2017","journal-title":"Dermatol Online J."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1016\/j.jsxm.2016.07.006","article-title":"Effect of 5\u03b1-reductase inhibitors on sexual function: a meta-analysis and systematic review of randomized controlled trials.","volume":"13","author":"Liu","year":"2016","journal-title":"J Sex Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"12","DOI":"10.2340\/00015555-3035","article-title":"Adverse sexual effects of treatment with finasteride or dutasteride for male androgenetic alopecia: a systematic review and meta-analysis.","volume":"99","author":"Lee","year":"2019","journal-title":"Acta Derm Venereol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B18","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1590\/S1677-5538.IBJU.2017.0531","article-title":"5-alpha reductase inhibitors and risk of male breast cancer: a systematic review and meta-analysis.","volume":"44","author":"Wang","year":"2018","journal-title":"Int Braz J Urol"},{"key":"B19","first-page":"400","article-title":"Long-term treatment with finasteride 1 mg decreases the likelihood of developing further visible hair loss in men with androgenetic alopecia (male pattern hair loss).","volume":"18","author":"Kaufman","year":"2008","journal-title":"Eur J Dermatol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/s0190-9622(98)70007-6","article-title":"Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group.","volume":"39","author":"Kaufman","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1346-8138.2011.01378.x","article-title":"Evaluation of efficacy and safety of finasteride 1 mg in 3177 Japanese men with androgenetic alopecia.","volume":"39","author":"Sato","year":"2012","journal-title":"J Dermatol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S0190-9622(99)70081-2","article-title":"Finasteride in the treatment of Japanese men with male pattern hair loss.","volume":"14","author":"Kawashima","year":"2004","journal-title":"Eur J Dermatol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/s0190-9622(99)70081-2","article-title":"Finasteride in the treatment of men with frontal male pattern hair loss.","volume":"40","author":"Leyden","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1046\/j.1365-2133.2000.03780.x","article-title":"Finasteride increases anagen hair in men with androgenetic alopecia.","volume":"143","author":"Van Neste","year":"2000","journal-title":"Br J Dermatol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jaad.2005.07.001","article-title":"Changes in hair weight in men with androgenetic alopecia after treatment with finasteride (1 mg daily): three- and 4-year results.","volume":"55","author":"Price","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1111\/j.1524-4725.2005.31202","article-title":"Effects of finasteride (1 mg) on hair transplant.","volume":"31","author":"Leavitt","year":"2005","journal-title":"Dermatol Surg"},{"key":"B27","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/dth.12246","article-title":"Combined treatment with oral finasteride and topical minoxidil in male androgenetic alopecia: a randomized and comparative study in Chinese patients.","volume":"28","author":"Hu","year":"2015","journal-title":"Dermatol Ther"},{"key":"B28","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1159\/000079595","article-title":"An open, randomized, comparative study of oral finasteride and 5% topical minoxidil in male androgenetic alopecia.","volume":"209","author":"Arca","year":"2004","journal-title":"Dermatology"},{"key":"B29","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/1346-8138.14719","article-title":"Evaluation of long-term efficacy of finasteride in Korean men with androgenetic alopecia using the basic and specific classification system.","volume":"46","author":"Shin","year":"2019","journal-title":"J Dermatol"},{"key":"B30","first-page":"555","article-title":"Clinical dose ranging studies with finasteride, a type 2 5alpha-reductase inhibitor, in men with male pattern hair loss.","volume":"41","author":"Roberts","year":"1999","journal-title":"J Am Acad Dermatol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/ijd.17957","article-title":"Is the safety of finasteride correlated with its route of administration: topical versus oral? A pharmacovigilance study with data from the United States Food and Drug Administration Adverse Event Reporting System.","volume":"65","author":"Gupta","year":"2026","journal-title":"Int J Dermatol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1111\/jdv.17738","article-title":"Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial.","volume":"36","author":"Piraccini","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"56","DOI":"10.4103\/ijt.ijt_72_22","article-title":"Comparative efficacy of topical finasteride (0.25%) in combination with minoxidil (5%) against 5% minoxidil or 0.25% finasteride alone in male androgenetic alopecia: a pilot, randomized open-label study.","volume":"15","author":"Bharadwaj","year":"2023","journal-title":"Int J Trichology"},{"key":"B34","doi-asserted-by":"publisher","first-page":"189","DOI":"10.3109\/09546639709160517","article-title":"Topical finasteride in the treatment of androgenic alopecia. Preliminary evaluations after a 16-month therapy course.","volume":"8","author":"Mazzarella","year":"1997","journal-title":"J Dermatol Treat."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1111\/jdv.15171","article-title":"A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil vs. 3% minoxidil solution in the treatment of male androgenetic alopecia.","volume":"32","author":"Suchonwanit","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"842","DOI":"10.5414\/CP202119","article-title":"A novel finasteride 0.25% topical solution for androgenetic alopecia: pharmacokinetics and effects on plasma androgen levels in healthy male volunteers.","volume":"52","author":"Caserini","year":"2014","journal-title":"Int J Clin Pharmacol Ther"},{"key":"B37","doi-asserted-by":"publisher","first-page":"19","DOI":"10.5414\/CP202467","article-title":"Effects of a novel finasteride 0.25% topical solution on scalp and serum dihydrotestosterone in healthy men with androgenetic alopecia.","volume":"54","author":"Caserini","year":"2016","journal-title":"Int J Clin Pharmacol Ther"},{"key":"B38","doi-asserted-by":"publisher","first-page":"241953","DOI":"10.5402\/2011\/241953","article-title":"Pilot study of 15 patients receiving a new treatment regimen for androgenic alopecia: the effects of atopy on AGA.","volume":"2011","author":"Rafi","year":"2011","journal-title":"ISRN Dermatol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.jaad.2009.09.018","article-title":"Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: a randomized, double-blind, placebo-controlled, phase III study.","volume":"63","author":"Eun","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1111\/1346-8138.13310","article-title":"Long-term safety and efficacy of dutasteride in the treatment of male patients with androgenetic alopecia.","volume":"43","author":"Tsunemi","year":"2016","journal-title":"J Dermatol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1111\/1346-8138.14329","article-title":"Prospective randomized study of sexual function in men taking dutasteride for the treatment of androgenetic alopecia.","volume":"45","author":"Tsai","year":"2018","journal-title":"J Dermatol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"489e","DOI":"10.1016\/j.jaad.2013.10.049","article-title":"A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.","volume":"70","author":"Gubelin Harcha","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.jaad.2006.05.007","article-title":"The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride.","volume":"55","author":"Olsen","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"349","DOI":"10.5021\/ad.22.027","article-title":"Long-term effectiveness and safety of dutasteride versus finasteride in patients with male androgenic alopecia in South Korea: a multicentre chart review study.","volume":"34","author":"Choi","year":"2022","journal-title":"Ann Dermatol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"47","DOI":"10.4103\/0378-6323.188652","article-title":"Superiority of dutasteride over finasteride in hair regrowth and reversal of miniaturization in men with androgenetic alopecia: a randomized controlled open-label, evaluator-blinded study.","volume":"83","author":"Shanshanwal","year":"2017","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"498","DOI":"10.9758\/cpn.2021.19.3.498","article-title":"The relationship between psychopathology, self-esteem, body perception and serum sex steroids in pubertal gynecomastia.","volume":"19","author":"Arslan","year":"2021","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"B47","doi-asserted-by":"publisher","first-page":"489","DOI":"10.4081\/aiua.2021.4.489","article-title":"Drug-induced gynecomastia: a systematic review and meta-analysis of randomized clinical trials.","volume":"93","author":"Trinchieri","year":"2021","journal-title":"Arch Ital Urol Androl"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1557988319871423","DOI":"10.1177\/1557988319871423","article-title":"Influence of postoperative finasteride therapy on recurrence of gynecomastia after mastectomy in men taking finasteride for alopecia.","volume":"13","author":"Lee","year":"2019","journal-title":"Am J Mens Health"},{"key":"B49","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1159\/000497362","article-title":"Post-finasteride syndrome: an induced delusional disorder with the potential of a mass psychogenic illness?","volume":"5","author":"Tr\u00fceb","year":"2019","journal-title":"Skin Appendage Disord"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1111\/j.1743-6109.2011.02255.x","article-title":"Persistent sexual side effects of finasteride for male pattern hair loss.","volume":"8","author":"Irwig","year":"2011","journal-title":"J Sex Med"},{"key":"B51","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1177\/1557988314538445","article-title":"Persistent sexual, emotional, and cognitive impairment post-finasteride: a survey of men reporting symptoms.","volume":"9","author":"Ganzer","year":"2015","journal-title":"Am J Mens Health"},{"key":"B52","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1007\/s12020-018-1593-5","article-title":"Post-finasteride syndrome and post-SSRI sexual dysfunction: two sides of the same coin?","volume":"61","author":"Giatti","year":"2018","journal-title":"Endocrine"},{"key":"B53","doi-asserted-by":"publisher","first-page":"4669","DOI":"10.1210\/jc.2016-2726","article-title":"Characteristics of men who report persistent sexual symptoms after finasteride use for hair loss.","volume":"101","author":"Basaria","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B54","doi-asserted-by":"publisher","first-page":"e3020","DOI":"10.7717\/peerj.3020","article-title":"Persistent erectile dysfunction in men exposed to the 5\u03b1-reductase inhibitors, finasteride, or dutasteride.","volume":"5","author":"Kiguradze","year":"2017","journal-title":"PeerJ"},{"key":"B55","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.abd.2022.09.006","article-title":"Female-pattern hair loss: therapeutic update.","volume":"98","author":"M\u00fcller Ramos","year":"2023","journal-title":"An Bras Dermatol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"951","DOI":"10.2147\/DDDT.S240615","article-title":"Finasteride and its potential for the treatment of female pattern hair loss: evidence to date.","volume":"14","author":"Iamsumang","year":"2020","journal-title":"Drug Des Devel Ther"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1345\/aph.1M591","article-title":"Finasteride treatment of hair loss in women.","volume":"44","author":"Stout","year":"2010","journal-title":"Ann Pharmacother"},{"key":"B58","doi-asserted-by":"publisher","first-page":"22","DOI":"10.4103\/0974-7753.114709","article-title":"Finasteride 5 mg\/day treatment of patterned hair loss in normo-androgenetic postmenopausal women.","volume":"5","author":"Oliveira-Soares","year":"2013","journal-title":"Int J Trichol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/j.1468-3083.2010.03758.x","article-title":"5 mg\/day finasteride treatment for normoandrogenic Asian women with female pattern hair loss.","volume":"25","author":"Yeon","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/s0015-0282(02)04551-x","article-title":"Treatment of hyperandrogenic alopecia in women.","volume":"79","author":"Carmina","year":"2003","journal-title":"Fertil Steril"},{"key":"B61","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1080\/gye.17.1.57.63","article-title":"The benefits of finasteride for hirsute women with polycystic ovary syndrome or idiopathic hirsutism.","volume":"17","author":"Lakryc","year":"2003","journal-title":"Gynecol Endocrinol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1210\/jcem.80.1.7829618","article-title":"A prospective randomized trial comparing finasteride to spironolactone in the treatment of hirsute women.","volume":"80","author":"Wong","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"B63","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1067\/mjd.2000.107953","article-title":"Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia.","volume":"43","author":"Price","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1002\/cam4.1273","article-title":"Finasteride treatment and male breast cancer: a register-based cohort study in four Nordic countries.","volume":"7","author":"Meijer","year":"2018","journal-title":"Cancer Med"},{"key":"B65","doi-asserted-by":"publisher","first-page":"e13182","DOI":"10.1111\/dth.13182","article-title":"Effectiveness and safety of oral dutasteride for male androgenetic alopecia in real clinical practice: a descriptive monocentric study.","volume":"33","author":"Va\u00f1\u00f3-Galv\u00e1n","year":"2020","journal-title":"Dermatol Ther"},{"key":"B66","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jaad.2024.09.028","article-title":"Analysis of breast health outcomes in women on oral 5-alpha reductase inhibitors: a single-center retrospective cohort study.","volume":"92","author":"Venkatesh","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1111\/ijd.17871","article-title":"Exposure to 5-alpha reductase inhibitors and spironolactone is not associated with increased odds of gynecologic tumors in a large cohort study of patients with alopecia.","volume":"64","author":"Singal","year":"2025","journal-title":"Int J Dermatol"},{"key":"B68","article-title":"Benign prostatic hyperplasia.","volume-title":"StatPearls.","author":"Ng","year":"2025"},{"key":"B69","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/s0090-4295(03)00045-1","article-title":"The role of dihydrotestosterone in benign prostatic hyperplasia.","volume":"61","author":"Carson","year":"2003","journal-title":"Urology"},{"key":"B70","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ajur.2017.11.005","article-title":"The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia.","volume":"5","author":"Kim","year":"2018","journal-title":"Asian J Urol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"113","DOI":"10.4212\/cjhp.v70i2.1643","article-title":"5\u03b1-reductase inhibitors for treatment of benign prostatic hyperplasia: a systematic review and meta-analysis.","volume":"70","author":"Jun","year":"2017","journal-title":"Can J Hosp Pharm"},{"key":"B72","doi-asserted-by":"publisher","first-page":"313","DOI":"10.21037\/tau-22-58","article-title":"The efficacy and safety of dutasteride and finasteride in patients with benign prostatic hyperplasia: a systematic review and meta-analysis.","volume":"11","author":"Li","year":"2022","journal-title":"Transl Androl Urol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1146\/annurev-pharmtox-022723-112425","article-title":"The nocebo effect.","volume":"64","author":"Colloca","year":"2024","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.genhosppsych.2007.01.010","article-title":"Nocebo effects with antidepressant clinical drug trial placebos.","volume":"29","author":"Reeves","year":"2007","journal-title":"Gen Hosp Psychiatry"},{"key":"B75","doi-asserted-by":"publisher","first-page":"R105753","DOI":"10.7554\/eLife.105753","article-title":"Nocebo effects are stronger and more persistent than placebo effects in healthy individuals.","volume":"14","author":"Kunkel","year":"2025","journal-title":"Elife"},{"key":"B76","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.fertnstert.2019.11.030","article-title":"Post-finasteride syndrome: a surmountable challenge for clinicians.","volume":"113","author":"Traish","year":"2020","journal-title":"Fertil Steril"},{"key":"B77","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.abd.2020.02.001","article-title":"Post-finasteride syndrome.","volume":"95","author":"Pereira","year":"2020","journal-title":"An Bras Dermatol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.4088\/JCP.12m07887","article-title":"Depressive symptoms and suicidal thoughts among former users of finasteride with persistent sexual side effects.","volume":"73","author":"Irwig","year":"2012","journal-title":"J Clin Psychiatry"},{"key":"B79","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s00428-021-03190-7","article-title":"Male breast cancer: an update.","volume":"480","author":"Fox","year":"2022","journal-title":"Virchows Arch"},{"key":"B80","first-page":"5917","article-title":"Estrogen activates telomerase.","volume":"59","author":"Kyo","year":"1999","journal-title":"Cancer Res."},{"key":"B81","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1210\/edrv.21.1.0386","article-title":"Is estradiol a genotoxic mutagenic carcinogen?","volume":"21","author":"Liehr","year":"2000","journal-title":"Endocr Rev"},{"key":"B82","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s10549-018-4996-3","article-title":"Safety of 5\u03b1-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies.","volume":"174","author":"Rozner","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"B83","doi-asserted-by":"publisher","first-page":"e41737","DOI":"10.7759\/cureus.41737","article-title":"Unveiling the role of hormonal imbalance in breast cancer development: a comprehensive review.","volume":"15","author":"Satpathi","year":"2023","journal-title":"Cureus"},{"key":"B84","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1001\/jamadermatol.2020.3385","article-title":"Investigation of suicidality and psychological adverse events in patients treated with finasteride.","volume":"157","author":"Nguyen","year":"2021","journal-title":"JAMA Dermatol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1787706\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T04:34:13Z","timestamp":1781757253000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1787706\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":84,"alternative-id":["10.3389\/fmed.2026.1787706"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1787706","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]},"article-number":"1787706"}}